Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

about

Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer

P2860

Q42333176-79559FCE-D6C7-467B-81BA-990E8E40094F Q57164771-9F5A2565-10D9-4929-AECC-D0C145FF9830

P2860

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

Item

http://www.wikidata.org/entity/Q40996798

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Oncology Drug Approvals: Evalu ...... Era of Breakthrough Therapies.

@en

type

Item

label

Oncology Drug Approvals: Evalu ...... Era of Breakthrough Therapies.

@en

prefLabel

Oncology Drug Approvals: Evalu ...... Era of Breakthrough Therapies.

@en

P1476

Oncology Drug Approvals: Evalu ...... Era of Breakthrough Therapies.

@en

P2093

Amy E McKee

http://www.w3.org/2001/XMLSchema#string

Gideon M Blumenthal

http://www.w3.org/2001/XMLSchema#string

Julie Schneider

http://www.w3.org/2001/XMLSchema#string

Kirsten B Goldberg

http://www.w3.org/2001/XMLSchema#string

Paul G Kluetz

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Improved survival in multiple myeloma and the impact of novel therapies.

Endpoints for assessing drug activity in clinical trials.

P304

762-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28576856

http://www.w3.org/2001/XMLSchema#string

P921

drug approval

P932

5507655

http://www.w3.org/2001/XMLSchema#string

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

about

P2860

P2860

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932